ClinicalTrials.gg
Sign In
RecruitingNCT05090943RegisTICsUpdated Sep 4, 2025

Adult Tic Disorders Registry

An observational study in Tic Disorders, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to develop the adult tic disorders registry in order to characterize the relationship between tic severity and tic-related impairment in women compared to men with tic disorders.

02

Conditions studied

  • Tic Disorders

Browse trials for

03

In context

Tic Disorders

102 studies on the registry are indexed under Tic Disorders; 26 are open to participants now.

This study's planned enrollment of 450 is above the median of 54 across 17 observational studies indexed under Tic Disorders.

Browse Tic Disorders studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Browse Assistance Publique - Hôpitaux de Paris studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with tics disorders

Eligibility criteria

Inclusion criteria :

  1. Age >18 years
  2. Patients with Tic disorders
  3. Given the non-opposition

Non Inclusion criteria

  1. No affiliation to a French health social insurance
  2. Significant congenital disorders that may affect understanding of assessments
  3. Patients under guardianship or curatorship
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Quality of life questionnaires

    Other: QOL to be completed by the participant

Interventions

  • OtherQOL to be completed by the participant

    The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant

06

What researchers measure

Primary outcomes

  1. Correlation between Quality of Life and TICs severity

    Severity of the tics measurement (YGTSS Impairment Score) and the quality of life (TS-QOL) between men and women with tic disorders, while controlling for the YGTSS Total Tic Score

    Time frame: 6 months

Secondary outcomes

  1. Change in TICs

    Change in tic inventories/tic migrations with the YGTSS tic inventories

    Time frame: 6 months

07

Study locations

7 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Dec 2027, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 25, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05090943
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Dec 1, 2021
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 4, 2025

Study contacts

Emmanuel Flamand-Roze, MD, PhD
Contact
emmanuel.flamand-roze@aphp.fr
1 42 16 06 45 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tic Disorders →

Other studies from this sponsor

Assistance Publique - Hôpitaux de Paris →

Start the discussion